ADC Therapeutics (ADCT) Common Equity (2020 - 2026)

ADC Therapeutics (ADCT) has reported Common Equity for 7 consecutive years, with -$216.4 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity rose 9.17% year-over-year to -$216.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$216.4 million (up 9.17% YoY) and the FY2025 annual result came in at -$185.8 million, up 8.29% from the prior year.
• Common Equity retreated to -$216.4 million in Q1 2026 per ADCT's latest filing, from -$185.8 million in the prior quarter.
• Over the last five years, Common Equity for ADCT reached as high as $162.7 million in Q1 2022 and fell as low as -$238.2 million in Q1 2025.
• A 5-year average of -$101.6 million and a median of -$160.1 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity sank 784.15% — and 2026, when it advanced 9.17%.
• Year by year, Common Equity stood at $79.5 million in 2022, then slumped by 286.59% to -$148.2 million in 2023, then sank by 36.69% to -$202.6 million in 2024, then climbed by 8.29% to -$185.8 million in 2025, then fell by 16.44% to -$216.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$216.4 million, -$185.8 million, and -$238.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.